Business Wire

Adoption of Denodo Coronavirus Data Portal Initiative Grows as More Customers and Partners Use It to Fight and Minimize the Impact of COVID-19

Share

Denodo, the leader in data virtualization, today announced increased adoption of its Coronavirus Data Portal (CDP), an open, cooperative effort that utilizes data virtualization to unify critical datasets originally exposed in different formats from multiple sources and countries. Originally developed in March during early onset of the pandemic, Denodo has combined and unified COVID-19 related intelligence and made it available to data consumers such as data scientists, analysts, and researchers who are leveraging the information to find solutions to this global disease. For more information, and to participate in the effort, visit https://www.coronavirusdataportal.com.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200902005272/en/

“In an effort to measure and monitor the health of our employees, we needed to create a way for them to tell us about their own health and to provide the clinical teams and leadership with details on who is healthy and who is not before coming to work,” said Mahendra Parasmal, Sr. Information Architect at Spectrum Health. “Denodo provides us with the ability to connect self-purported health data provided by employees via an online survey with employee demographics, employee hierarchy, badge system & Active Directory data virtually. This delivers wellness information in near real-time without having to Extract, Transform & Load the data physically from source systems or run batch incremental loads. As a result, we have been able to speed up our overall build time by at least 3x and deliver the end result in weeks instead of months.”

Free of charge to participants, the Coronavirus Data Portal enables organizations and institutions to share their individual data sets that Denodo integrates and offers to the broader community for consumption via the data platform. It also allows members to integrate and curate these data sets so they can augment their own COVID-19 initiatives. As of today, there are 64 sources, 220 datasets, and 441 views offered on CDP.

“I can personally attest to how our company was able to leverage Denodo’s Coronavirus Data Portal having developed a COVID-19 virtual hub that provides reports based on data science and pmOne Share,” said Dr. Norman Bernhardt, Head of Digital Solutions R&D, pmOne. “pmOne Share Cockpit aggregates existing and established reporting solutions and provides advanced filtering capabilities, which data scientists can use to develop algorithms to analyze global news flows, the results of which are displayed in a dashboard.”

More specifically, Denodo’s CDP is being used to:

  • Search the Curated Datasets: Coronavirus Data Portal offers a catalog of the curated data sets - both uploaded and curated by Denodo data stewards and those contributed by users of the data portal. This allows users to search the available data sets and find the data relevant to them such as details about the spread of the disease, school closures, financial impact, etc. It also enables them to drill deeper to view details about a particular data set and its relationship with other ones.
  • Enhance Dashboard BI Tools with Integrated Data Portal: CDP supports BI tools such as Power BI, Tableau and others so participants can connect to the data portal and generate smart visualizations. Users can use these tools to easily create new customized reports of the integrated data.
  • Extend Data integration Using API Service/Downloadable CSV Datasets: Lets users further integrate their application with the Coronavirus Data Platform, utilizing it as an API service layer. This enables users to access the curated data sets in a variety of views and is an option that is growing significantly as more and more multi-faceted data is added from across the globe.
  • Contribute to the Initiative: The Coronavirus Data Portal is an open platform, which permits users to contribute their own data sets to the initiative. It suggests data sources that should be added to the Data Portal and Denodo’s data steward team will review the data and usage permissions to determine if it’s appropriate to be uploaded. Alternatively, they can create new data sets by combining the Coronavirus Data Portal data with their own data and share this new data set with other Data Portal users.

“While our data stewards and data engineers have been working behind the scenes to add more data sets to the Coronavirus Data Portal, we have also been getting some great suggestions from the user community. Based on suggestions, we’ve added COVID-19 forecast data, real-time information about how many are infected and where, school closures, global news as they are published, and much more,” said Angel Viña, CEO and Founder at Denodo. “Contributing data sets - either through suggestions or by creating derived data sets - will continue the growth of the Coronavirus Data Portal and enhance the value that fellow users are getting from using the data. This continued growth will provide more varied and richer data for all of us to use and share in our efforts to combat this deadly pandemic.”

Please Tweet: News: #datavirtulization provider @denodo offers complimentary #coronavirus data portal to unify #datasets and information to fight #COVID19

About Denodo

Denodo is the leader in data virtualization providing agile, high performance data integration, data abstraction, and real-time data services across the broadest range of enterprise, cloud, big data, and unstructured data sources at half the cost of traditional approaches. Denodo’s customers across every major industry have gained significant business agility and ROI by enabling faster and easier access to unified business information for agile BI, big data analytics, Web, cloud integration, single-view applications, and enterprise data services. Denodo is well-funded, profitable, and privately held. For more information, visit http://www.denodo.com or call +1 877 556 2531 / +44 (0) 20 7869 8053.

Contact information

Chris McCoin or Richard Smith
McCoin & Smith Communications Inc.
508-429-5988 (Chris) or 978-433-3304 (Rick)
chris@mccoinsmith.com or rick@mccoinsmith.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda Presents New Data Highlighting Scientific Advancements in Lung Cancer at ESMO Virtual Congress18.9.2020 13:55:00 EESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the company is presenting data from its lung cancer portfolio at the virtual European Society for Medical Oncology (ESMO) conference. Notably, insights from sub-analyses of the Phase 3 ALTA 1L study reinforce both the compelling evidence of intracranial efficacy with ALUNBRIG® (brigatinib) as a first-line treatment for patients with anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) as well as associated quality of life (QoL) data. Takeda is also featuring updated 10-month follow-up results from the Phase 1/2 trial of mobocertinib (TAK-788), demonstrating mobocertinib achieved a duration of response (DoR) of more than one year in the trial’s study population of patients with epidermal growth factor receptor (EGFR) Exon20 insertion+ metastatic NSCLC (mNSCLC). “We’re pleased to present our ongoing research in lung cancer at this year’s virtual ESMO congress, including new

Incyte Announces Encouraging Results From Phase 2 Trial of Retifanlimab (INCMGA0012) in Patients With Previously Treated, Advanced Squamous Cell Carcinoma of the Anal Canal18.9.2020 13:00:00 EESTPress release

Incyte (Nasdaq:INCY) today announced results from its Phase 2 POD1UM-202 trial evaluating retifanlimab, a PD-1 inhibitor, in previously treated patients with advanced squamous cell carcinoma of the anal canal (SCAC) who have progressed following standard platinum-based chemotherapy. The trial enrolled 94 patients, including those with well-controlled human immunodeficiency virus (HIV) infection (10%). Retifanlimab monotherapy resulted in a confirmed objective response rate (ORR) of 14% as determined by independent central review (ICR) using RECIST v1.1. Responses were observed regardless of PD-L1 status, presence of liver metastases, age or HIV+ status. Retifanlimab was generally well-tolerated with a safety profile as expected of a PD-1 inhibitor and no loss of HIV infection control. Key findings from POD1UM-202: N=94 ORR* (95% CI) 13.8% (7.6-22.5) Best OR*, n 1 CR 12 PR 33 SD DCR 48.9% DOR, median (95% CI), months 9.5 (5.6-NE) PFS, median (95% CI), months 2.3 (1.9-3.6) OS, median (95

Sigfox and Cube Infrastructure Managers Announce Major Partnership in IoT Infrastructure18.9.2020 10:30:00 EESTPress release

Sigfox, the global 0G network1 and cloud provider for industrial data, is proud to announce a new strategic alliance with Cube Infrastructure Managers (Cube), through the sale of its German 0G network to Cube. Sigfox has grown its 0G IoT services by rolling out 0G networks across 72 countries and regions, which was largely achieved with partners called Sigfox Operators. These operators are the owners of the 0G networks, which they operate as exclusive connectivity providers of Sigfox IoT services, offering worldwide connectivity to customers. The sale of the German network to Cube will allow Sigfox to finance its continued innovation efforts in data value extraction and improvements in cloud algorithms to reduce energy consumption and allow the implementation of even more cost-effective devices and sensors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200918005116/en/ Cube Infrastructure Managers, the European infrastructu

Sensorion successfully raises approximately €31 (US$ 36.5) million in an oversubscribed private placement to US and European investors18.9.2020 09:00:00 EESTPress release

Regulatory News: Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia or Japan. This press release is not intended as an offer and is for informational purpose only Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN – the “Company”) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders announces today the success of its previously announced capital increase. The Company has placed 18,236,000 new ordinary shares with a nominal value of €0.10 each (the “New Shares”), for total gross proceeds of approximately € 31 million by means of an accelerated bookbuild offering to the benefit of categories of persons (the “Reserved Offering”). The issue price of the New Shares is €1.70 per share, representing a 3.5% discount to the weighted average share price on the day preceding the date on which the issuance price

ESMO 2020: Phase II CLARINET FORTE Results Show Increasing Dose Frequencies of Somatuline® Autogel® (lanreotide) Allows Patients with NETs to Delay Treatment Escalation by up to 8.3 Months18.9.2020 08:00:00 EESTPress release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the release of first efficacy and safety data from the CLARINET FORTE study, with the abstract to be presented as a mini-oral presentation at the 2020 European Society for Medical Oncology (ESMO) Congress, taking place virtually from 19-21 September 2020. The prospective single-arm, open-label, exploratory, international Phase II study investigated the efficacy and safety of increasing the dose frequency of Somatuline® Autogel ® (lanreotide) in patients with pancreatic or midgut NETs with centrally-assessed progression within the last two years while on a standard lanreotide regimen for ≥24 weeks. An extension of progression-free survival (PFS) rates and encouraging disease-control rates (DCR) were recorded in both tumor types, with no new safety signals. “These results support a clinically meaningful benefit to a population of patients with high unmet medical need by potentially delaying escalation to more toxic treatm

Vifor Pharma Group Announces Successful Sale of OM Pharma18.9.2020 08:00:00 EESTPress release

Regulatory News: Vifor Pharma has today announced the successful sale of 100% of the share capital of OM Pharma, a Vifor Pharma Group company to Optimus Holding Ltd. The terms of the deal include: A purchase consideration of MCHF 435 for 100% of the share capital An earn out related to potential future value gains on 20% of Optimus Holding Ltd. equity to be determined before the end of 2027 upon a trade sale, IPO or EBITDA multiple This earn out together with the purchase consideration could result in a total transaction value exceeding MCHF 500. The deal is expected to close within 30 days. OM Pharma is a Geneva-based company mainly active in the field of microbial derived immunotherapeutics and has developed strongly outside the core strategy of Vifor Pharma over the past few years. Optimus Holding Ltd. is a Swiss Group, founded by Etienne Jornod together with long-standing Swiss entrepreneurs and Abdi Ibrahim (28.5%), a Turkey-based pharmaceutical company operating in 12 countries a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom